|
1
|
Deininger MW, Goldman JM and Melo JV: The
molecular biology of chronic myeloid leukemia. Blood. 96:3343–3356.
2000.PubMed/NCBI
|
|
2
|
Corbin AS, La Rosée P, Stoffregen EP,
Druker BJ and Deininger MW: Several Bcr-Abl kinase domain mutants
associated with imatinib mesylate resistance remain sensitive to
imatinib. Blood. 101:4611–4614. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Litzow MR: Imatinib resistance, obstacles
and opportunities. Arch Pathol Lab Med. 130:669–679.
2006.PubMed/NCBI
|
|
4
|
Wongboonma W, Thongnoppakhun W and
Auewarakul CU: BCR-ABL kinase domain mutations in tyrosine kinase
inhibitors-naïve and -exposed Southeast Asian chronic myeloid
leukemia patients. Exp Mol Pathol. 92:259–265. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sawyers CL: Chronic myeloid leukemia. N
Engl J Med. 340:1330–1340. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
O'Brien S, Berman E, Borghaei H, DeAngelo
DJ, Devetten MP, Devine S, Erba HP, Gotlib J, Jagasia M, Moore JO,
et al: NCCN clinical practice guidelines in oncology: Chronic
myelogenous leukemia. J Natl Compr Canc Netw. 7:984–1023. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Iqbal N and Iqbal N: Imatinib: A
breakthrough of targeted therapy in cancer. Chemother Res Pract.
2014:3570272014.PubMed/NCBI
|
|
8
|
Soverini S, Hochhaus A, Nicolini FE,
Gruber F, Lange T, Saglio G, Pane F, Müller MC, Ernst T, Rosti G,
et al: BCR-ABL kinase domain mutation analysis in chronic myeloid
leukemia patients treated with tyrosine kinase inhibitors:
Recommendations from an expert panel on behalf of European Leukemia
net. Blood. 118:1208–1215. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ursan ID, Jiang R, Pickard EM, Lee TA, Ng
D and Pickard AS: Emergence of BCR-ABL kinase domain mutations
associated with newly diagnosed chronic myeloid leukemia: A
meta-analysis of clinical trials of tyrosine kinase inhibitors. J
Manag Care Spec Pharm. 21:114–122. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
La Rosée P and Deininger MW: Resistance to
imatinib: Mutations and beyond. Semin Hematol. 47:335–343. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vaidya S, Vundinti BR, Shanmukhaiah C,
Chakrabarti P and Ghosh K: Evolution of BCR/ABL gene mutation in
CML is time dependent and dependent on the pressure exerted by
tyrosine kinase inhibitor. PLoS One. 10:e01148282015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Z, Liu Z, Wu X, Chu S, Wang J, Yuan
H, Roth M, Yuan YC, Bhatia R and Chen WY: Correction: ATRA-induced
cellular differentiation and CD38 expression inhibits acquisition
of BCR-ABL mutations for CML acquired resistance. PLoS Genet.
10:e10044142014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cortes J, Jabbour E, Kantarjian H, Yin CC,
Shan J, O'Brien S, Garcia-Manero G, Giles F, Breeden M, Reeves N,
et al: Dynamics of BCR-ABL kinase domain mutations in chronic
myeloid leukemia after sequential treatment with multiple tyrosine
kinase inhibitors. Blood. 110:4005–4011. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Apperley JF: Part I: Mechanisms of
resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol.
8:1018–1029. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jabbour E, Hochhaus A, Cortes J, La Rosée
P and Kantarjian HM: Choosing the best treatment strategy for
chronic myeloid leukemia patients resistant to imatinib: Weighing
the efficacy and safety of individual drugs with BCR-ABL mutations
and patient history. Leukemia. 24:6–12. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Baccarani M, Castagnetti F, Gugliotta G
and Rosti G: A review of the european leukemianet recommendations
for the management of CML. Ann Hematol. 94 Suppl 2:S141–S147. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ai J and Tiu RV: Practical management of
patients with chronic myeloid leukemia who develop tyrosine kinase
inhibitor-resistant BCR-ABL1 mutations. Ther Adv Hematol.
5:107–120. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sorel N, Roy L, Martineau G, Guilhot F,
Turhan AG and Chomel JC: Sequential emergence of ABL-kinase
mutations with loss of unmutated BCR-ABL allele during targeted
therapies of CML. Blood. 108:1782–1783. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ernst T, Erben P, Muller MC, Paschka P,
Schenk T, Hoffmann J, Kreil S, La Rosée P, Hehlmann R and Hochhaus
A: Dynamics of BCR-ABL mutated clones prior to hematologic or
cytogenetic resistance to imatinib. Haematologica. 93:186–192.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Deininger MW, McGreevey L, Willis S,
Bainbridge TM, Druker BJ and Heinrich MC: Detection of ABL kinase
domain mutations with denaturing high performance liquid
chromatography. Leukemia. 18:864–871. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Iqbal Z, Aleem A, Iqbal M, Naqvi MI, Gill
A, Taj AS, Qayyum A, ur-Rehman N, Khalid AM, Shah IH, et al:
Sensitive detection of pre-existing BCR-ABL kinase domain mutations
in CD34+ cells of newly diagnosed chronic-phase chronic myeloid
leukemia patients is associated with imatinib resistance:
Implications in the post-imatinib era. PLoS One. 8:e557172013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Erbilgin Y, Çatal S, Eşkazan AE, Hatirnaz
Ö, Soysal T and Özbek U: ABL gene kinase domain mutation scanning
by denaturing high performance liquid chromatography sequencing
method. Turk J Hematol. 28:97–102. 2011. View Article : Google Scholar
|
|
23
|
Kang HY, Hwang JY, Kim SH, Goh HG, Kim M
and Kim DW: Comparison of allele specific
oligonucleotide-polymerase chain reaction and direct sequencing for
high throughput screening of ABL kinase domain mutations in chronic
myeloid leukemia resistant to imatinib. Haematologica. 91:659–662.
2006.PubMed/NCBI
|
|
24
|
Srivastava S and Dutt S: Imatinib mesylate
resistance and mutations: An Indian experience. Indian J Med
Paediatr Oncol. 34:213–220. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sherbenou DW, Hantschel O, Kaupe I, Willis
S, Bumm T, Turaga LP, Lange T, Dao K, Press RD, Druker BJ, et al:
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia
patients on imatinib. Blood. 116:3278–3285. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gruber F, Hansen H, Olsen M, Eggen L,
Skogen B, Gedde-Dahl T, Lundan T, Porkka K, Simonsson B, Markevärn
B, et al: Quantitative analyses of BCR-ABL mutations associated
with imatinib treatment in CML. Blood. 106:20002005.
|
|
27
|
Khorashad JS, Kelley TW, Szankasi P, Mason
CC, Soverini S, AdriaL T, Eide CA, Zabriskie MS, Lange T, Estrada
JC, et al: BCR-ABL1 compound mutations in tyrosine kinase
inhibitor-resistant CML: Frequency and clonal relationships. Blood.
121:489–498. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rajasekaran R, Doss PDC, Prasad GA and
Sethumadhavan R: In silico identification and analysis of drug
resistant mutants of ABL tyrosine kinase based on detrimental
missense mutations. Curr Signal Trans Ther. 6:396–404. 2011.
View Article : Google Scholar
|
|
29
|
von Bubnoff N, Veach DR, van der Kuip H,
Aulitzky WE, Sänger J, Seipel P, Bornmann WG, Peschel C, Clarkson B
and Duyster J: A cell-based screen for resistance of
Bcr-Abl-positive leukemia identifies the mutation pattern for
PD166326, an alternative Abl kinase inhibitor. Blood.
105:1652–1659. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Soverini S, Baccarani M, Iacobucci I and
Martinelli G: Resistance to tyrosine kinase inhibitors in
Philadelphia chromosome-positive leukemias: Which mutations matter?
Clinical Leukemia. 1:223–228. 2007. View Article : Google Scholar
|
|
31
|
Chomel JC, Sorel N and Turhan AG:
ABL-Kinase mutations in progenitors and stem cells from chronic
myeloid leukemia patients. Stem Cells Cancer Stem Cells. 8:305–315.
2012. View Article : Google Scholar
|
